| 2009 | A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2017 | A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
| CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2007 | A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2016 | A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | A prospective phase II trial of s-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2010 | A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2016 | A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2015 | A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2017 | Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2013 | Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2013 | Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2015 | Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2007 | Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG) | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2010 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2013 | Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2015 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2019 | Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors | Cancer Chemotherapy and Pharmacology |
| 2017 | Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2018 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2011 | Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
| CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2020 | Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
